Us Bancorp \De\ Bridge Bio Pharma, Inc. Transaction History

Us Bancorp \De\

$73 Billion
Q2 2024

A detailed history of Us Bancorp \De\ transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 9,597 shares of BBIO stock, worth $239,349. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,597

Previous 9,269 3.54%

Holding current value

$239,349

Previous $286,000 15.03%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$23.0 - $31.04 $7,544 - $10,181	328 Added 3.54%	9,597 $243,000
Q1 2024 May 07, 2024	SELL	$27.35 - $40.45 $174,684 - $258,354	-6,387 Reduced 40.8%	9,269 $286,000
Q4 2023 Feb 09, 2024	SELL	$24.02 - $43.89 $122,021 - $222,961	-5,080 Reduced 24.5%	15,656 $632,000
Q3 2023 Nov 03, 2023	SELL	$16.89 - $35.01 $159,779 - $331,194	-9,460 Reduced 31.33%	20,736 $546,000
Q2 2023 Aug 09, 2023	SELL	$13.29 - $18.01 $10,698 - $14,498	-805 Reduced 2.6%	30,196 $519,000
Q1 2023 May 09, 2023	BUY	$7.17 - $18.55 $212,210 - $549,024	29,597 Added 2108.05%	31,001 $513,000
Q4 2022 Feb 13, 2023	SELL	$6.74 - $11.52 $3,754 - $6,416	-557 Reduced 28.4%	1,404 $10,000
Q3 2022 Oct 27, 2022	BUY	$7.94 - $12.36 $976 - $1,520	123 Added 6.69%	1,961 $19,000
Q2 2022 Aug 01, 2022	BUY	$5.21 - $12.14 $5,720 - $13,329	1,098 Added 148.38%	1,838 $17,000
Q1 2022 May 11, 2022	BUY	$7.34 - $17.16 $4,925 - $11,514	671 Added 972.46%	740 $8,000
Q3 2021 Nov 10, 2021	SELL	$46.87 - $64.24 $562 - $770	-12 Reduced 14.81%	69 $3,000
Q2 2021 Aug 05, 2021	BUY	$46.47 - $63.93 $1,998 - $2,748	43 Added 113.16%	81 $5,000
Q1 2021 Apr 28, 2021	BUY	$55.47 - $72.35 $2,107 - $2,749	38 New	38 $2,000

Others Institutions Holding BBIO

# of Institutions

292

Shares Held

175M

Call Options Held

8.66M

Put Options Held

2.76M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $3.7B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account